<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "https://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="1.2" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJMABHR</journal-id>
<journal-title-group><journal-title>International Journal of Medical and All Body Health Research</journal-title><abbrev-journal-title>IJMABHR</abbrev-journal-title></journal-title-group>
<issn pub-type="epub">2582-8940</issn>
<publisher><publisher-name>Anfo Publication House</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">548</article-id>
<article-id pub-id-type="doi">10.54660/IJMBHR.2022.3.1.87-103</article-id>
<title-group><article-title>Development of the OncoSignal Algorithm for Detecting Low Abundance Circulating Tumor DNA Signals Compared with Conventional Threshold Based and Machine Learning Detection</article-title></title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><name><surname>Oni</surname><given-names>Rukayat Olayemi</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author"><name><surname>Adeyeye</surname><given-names>Yewande Iyimide</given-names></name><xref ref-type="aff" rid="aff2"/></contrib>
<aff id="aff1"><label>1</label>Department of Biology, Georgia State University, Atlanta, Georgia</aff>
<aff id="aff2"><label>2</label>Department of Day Case Surgery, Dumfries and Galloway Royal Infirmary, Dumfries, United Kingdom</aff>
</contrib-group>
<pub-date publication-format="electronic" date-type="pub"><year>2022</year></pub-date>
<volume>3</volume>
<issue>1</issue>
<fpage>87</fpage>
<lpage>103</lpage>
<history>
<date date-type="received"><day>05</day><month>02</month><year>2022</year></date>
<date date-type="accepted"><day>03</day><month>03</month><year>2022</year></date>
</history>
<permissions><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-sa/4.0/?utm"><license-p>CC BY-NC-SA 4.0</license-p></license></permissions>
<self-uri xlink:href="https://www.allmedicaljournal.com/article/548/development-of-the-oncosignal-algorithm-for-detecting-low-abundance-circulating-tumor-dna-signals"/>
<self-uri content-type="pdf" xlink:href="https://www.allmedicaljournal.com/article/548/download"/>
<abstract><p>Circulating tumor DNA (ctDNA) provides a minimally invasive molecular signal for cancer detection, residual disease assessment, treatment-response monitoring, and recurrence surveillance; however, reliable identification becomes difficult when tumor-derived fragments occur at very low variant allele fractions within a dominant background of normal cell-free DNA. This study develops OncoSignal, a novel computational algorithm for detecting low-abundance ctDNA through integrated background-error modelling, fragment-level signal weighting, molecular-context encoding, adaptive denoising, probabilistic evidence fusion, and confidence-calibrated classification. Unlike conventional fixed-threshold approaches that classify candidate variants primarily according to read depth, allele frequency, or predefined quality cut-offs, OncoSignal constructs a multidimensional evidence score from variant allele frequency, base quality, mapping quality, strand consistency, fragment length, genomic context, local sequencing error, molecular support, and locus-specific noise characteristics. The proposed architecture incorporates an Adaptive Molecular Noise Suppression module, Fragment-Context Attention Network, Bayesian Evidence Fusion layer, and Dynamic Signal Decision Boundary, allowing the detection threshold to adjust to sequencing depth, background error distribution, and sample-specific noise. OncoSignal is designed for comparative benchmarking against conventional variant allele frequency thresholding, statistical binomial detection, logistic regression, support vector machine, random forest, XGBoost, multilayer perceptron, one-dimensional convolutional neural networks, long short-term memory networks, and Transformer-based classifiers. Performance is evaluated across progressively decreasing ctDNA fractions using sensitivity, specificity, precision, F1-score, Matthews correlation coefficient, area under the receiver operating characteristic curve, area under the precision-recall curve, false-positive rate, calibration error, signal-to-noise ratio, and limit of detection. Particular emphasis is placed on the clinically demanding low-abundance interval below 1% variant allele frequency and the ultra-low range below 0.1%. Comparative graphical analysis includes ROC and precision-recall curves, sensitivity-versus-variant-allele-frequency profiles, three-dimensional surfaces relating sequencing depth, tumor fraction, and detection probability, calibration plots, signal-to-noise distributions, and error-rate comparisons across algorithms. The central hypothesis is that adaptive integration of molecular evidence and locus-specific background modelling will preserve true weak tumor signals while suppressing sequencing artefacts more effectively than fixed thresholds and conventional machine-learning classifiers. The resulting OncoSignal framework is intended to provide a more sensitive, specific, interpretable, and technically robust computational platform for low-abundance ctDNA detection and subsequent liquid-biopsy applications.</p></abstract>
<kwd-group kwd-group-type="author"><kwd>OncoSignal Algorithm</kwd><kwd>Circulating Tumor DNA</kwd><kwd>Low-Abundance ctDNA</kwd><kwd>Fragmentomics</kwd><kwd>Bayesian Evidence Fusion</kwd><kwd>Machine Learning</kwd></kwd-group>
</article-meta>
</front>
<back><ref-list><title>References</title>
<ref id="R1"><label>1</label><mixed-citation>Atalor SI. Data-driven cheminformatics models for predicting bioactivity of natural compounds in oncology. Int J Sci Res Mod Technol. 2022;1(1):65-76. doi:10.38124/ijsrmt.v1i1.496.</mixed-citation></ref>
<ref id="R2"><label>2</label><mixed-citation>Nwokocha CR, Peter-Anyebe AC, Ijiga OM. Evaluating FHIR-driven interoperability frameworks for secure system migration and data exchange in U.S. health information networks. Int J Sci Res Sci Technol. 2021. doi:10.32628/IJSRST523105135.</mixed-citation></ref>
<ref id="R3"><label>3</label><mixed-citation>Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223-238. doi:10.1038/nrc.2017.7.</mixed-citation></ref>
<ref id="R4"><label>4</label><mixed-citation>Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:44 6-451. doi:10.1038/nature22364.</mixed-citation></ref>
<ref id="R5"><label>5</label><mixed-citation>ames UU. Machine learning-driven anomaly detection for supply chain integrity in 5G industrial automation systems. Int J Sci Res Sci Eng Technol. 2022;9(2). doi:10.32628/IJSRSET22549.</mixed-citation></ref>
<ref id="R6"><label>6</label><mixed-citation>Idika CN, Salami EO, Ijiga OM, Enyejo LA. Deep learning driven malware classification for cloud-native microservices in edge computing architectures. Int J Sci Res Comput Sci Eng Inf Technol. 2021;7(4). doi:10.32628/CSEIT182551.</mixed-citation></ref>
<ref id="R7"><label>7</label><mixed-citation>Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403). doi:10.1126/scitranslmed.aan2415.</mixed-citation></ref>
<ref id="R8"><label>8</label><mixed-citation>Zviran A, Schulman RC, Shah M, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020;26:1114-1124. doi:10.1038/s41591-020-0915-3.</mixed-citation></ref>
<ref id="R9"><label>9</label><mixed-citation>Amebleh J, Igba E, Ijiga OM. Graph-based fraud detection in open-loop gift cards: heterogeneous GNNs, streaming feature stores, and near-zero-lag anomaly alerts. Int J Sci Res Sci Eng Technol. 2021;8(6). doi:10.32628/IJSRSET214418.</mixed-citation></ref>
<ref id="R10"><label>10</label><mixed-citation>Idika CN. Lightweight authentication mechanisms for securing wearable medical devices in body area networks. Glob J Multidiscip Stud. 2022;11(9). doi:10.5281/zenodo.17519630.</mixed-citation></ref>
<ref id="R11"><label>11</label><mixed-citation>Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34:547-555. doi:10.1038/nbt.3520.</mixed-citation></ref>
<ref id="R12"><label>12</label><mixed-citation>Razavi P, Li BT, Brown DN, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25:1928-1937. doi:10.1038/s41591-019-0652-7.</mixed-citation></ref>
<ref id="R13"><label>13</label><mixed-citation>Atalor SI. Federated learning architectures for predicting adverse drug events in oncology without compromising patient privacy. ICONIC Res Eng J. 2019;2(12).</mixed-citation></ref>
<ref id="R14"><label>14</label><mixed-citation>Kwarteng RA, Idoko IP, Ijiga OM, Enyejo LA. Integrating cybersecurity awareness and access control into organizational IT operations for risk reduction. Int J Sci Res Comput Sci Eng Inf Technol. 2020;6(1):243-261. doi:10.32628/CSEIT23906128.</mixed-citation></ref>
<ref id="R15"><label>15</label><mixed-citation>Mouliere F, Chandrananda D, Piskorz AM, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466). doi:10.1126/scitranslmed.aat4921.</mixed-citation></ref>
<ref id="R16"><label>16</label><mixed-citation>Kurtz DM, Soo J, Co Ting Keh L, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021;39:1537 -1547. doi:10.1038/s41587-021-00981-w.</mixed-citation></ref>
<ref id="R17"><label>17</label><mixed-citation>Ijiga OM, Anim-Sampong SD, Ilesanmi MO. Land use optimization for utility-scale solar and wind projects: integrating estate management and technology-driven site analytics. Int J Sci Res Sci Eng Technol. 2022;9(6):505-510. doi:10.32628/IJSRSET25122274.</mixed-citation></ref>
<ref id="R18"><label>18</label><mixed-citation>Ijiga OM, Ifenatuora GP, Olateju M. Digital storytelling as a tool for enhancing STEM engagement: a multimedia approach to science communication in K-12 education. Int J Multidiscip Res Growth Eval. 2021;2(5):495-505. doi:10.54660/IJMRGE.2021.2.5.495-505.</mixed-citation></ref>
<ref id="R19"><label>19</label><mixed-citation>Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570:385-389. doi:10.1038/s41586-019-1272-6.</mixed-citation></ref>
<ref id="R20"><label>20</label><mixed-citation>Chabon JJ, Hamilton EG, Kurtz DM, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020;580:245 -251. doi:10.1038/s41586-020-2140-0.</mixed-citation></ref>
<ref id="R21"><label>21</label><mixed-citation>Lo YMD, Han DSC, Jiang P, Chiu RWK. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science. 2021;372(6538). doi:10.1126/science.aaw3616.</mixed-citation></ref>
<ref id="R22"><label>22</label><mixed-citation>Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25(12):1928-1937. doi:10.1038/s41591-019-0652-7.</mixed-citation></ref>
<ref id="R23"><label>23</label><mixed-citation>Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):547 -555. doi:10.1038/nbt.3520.</mixed-citation></ref>
<ref id="R24"><label>24</label><mixed-citation>Zviran A, Schulman RC, Shah M, Hill STK, Deochand S, Khamnei CC, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020;26:1114 -1124. doi:10.1038/s41591-020-0915-3.</mixed-citation></ref>
<ref id="R25"><label>25</label><mixed-citation>Mathios D, Johansen JS, Cristiano S, Medina JE, Phallen J, Larsen KR, et al. Detection and characterization of International Journal of Medical and All Body Health Research www.allmedicaljournal.com lung cancer using cell-free DNA fragmentomes. Nat Commun. 2021;12:5060. doi:10.1038/s41467-021-24994-w.</mixed-citation></ref>
<ref id="R26"><label>26</label><mixed-citation>Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018;563(7732):579-583. doi:10.1038/s41586-018-0703-0.</mixed-citation></ref>
<ref id="R27"><label>27</label><mixed-citation>Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell. 2016;164(1-2):57-68. doi:10.1016/j.cell.2015.11.050.</mixed-citation></ref>
<ref id="R28"><label>28</label><mixed-citation>Ulz P, Thallinger GG, Auer M, Graf R, Kashofer K, Jahn SW, et al. Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat Genet. 2016;48(10):1273-1278. doi:10.1038/ng.3648.</mixed-citation></ref>
<ref id="R29"><label>29</label><mixed-citation>Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548 -554. doi:10.1038/nm.3519.</mixed-citation></ref>
<ref id="R30"><label>30</label><mixed-citation>Adalsteinsson VA, Ha G, Freeman SS, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8:1324. doi:10.1038/s41467-017-00965-y.</mixed-citation></ref>
<ref id="R31"><label>31</label><mixed-citation>Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34:547-555. doi:10.1038/nbt.3520.</mixed-citation></ref>
<ref id="R32"><label>32</label><mixed-citation>Mathios D, Johansen JS, Cristiano S, et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat Commun. 2021;12:5060. doi:10.1038/s41467-021-24994-w.</mixed-citation></ref>
<ref id="R33"><label>33</label><mixed-citation>Zviran A, Schulman RC, Shah M, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020;26:1114-1124. doi:10.1038/s41591-020-0915-3.</mixed-citation></ref>
</ref-list></back>
</article>